Tweet MIAMI, FL, Aegle Therapeutics today announced the closing of a $4M financing.

To export Aegle Therapeutics funding data to PDF and Excel, clickClick here for more funding data on Aegle TherapeuticsTo export Aegle Therapeutics funding data to PDF and Excel, click here Aegle Therapeutics, a first in class biotechnology company isolating extracellular vesicles, including exosomes ("EVs"), secreted by mesenchymal stem cells as therapy, today announced the closing of a $4M financing.

Aegle's platform technology is initially being developed to treat dystrophic epidermolysis bullosa ("DEB"), a rare pediatric skin blistering disorder.

Aegle's technology is based on decades of work conducted by Dr. Evangelos Badiavas, M.D., Ph.D., Aegle's founder.

About Aegle Therapeutics Corp.Aegle Therapeutics (www.aegletherapeutics.com) is a privately-held biotechnology company developing a first in class therapy using extracellular vesicles ("EVs"), including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells. | To read full story, visit https://startuparound.com/read/1578457807.214006/Aegle-Therapeutics-Announces-$4M-Financing?ref=audio_experience